Home Biosimilar Antibodies Others Others Rovalpituzumab (Anti-DLL3)
For research use only. Not for use in humans.

Rovalpituzumab (Anti-DLL3)

Synonyms: MBD3， Dipeptidase 3

Rovalpituzumab (Anti-DLL3) is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). MW: 145.5 KD.

Rovalpituzumab (Anti-DLL3)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet
99

Mechanism of Action

Description
Rovalpituzumab (Anti-DLL3) is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). MW: 145.5 KD.

Product Details

CAS No. 1613313-01-1
Molecular Weight 150 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)		 Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT07488923 RECRUITING Small Cell Lung Cancer (SCLC ); Extrapulmonary Neuroendocrine Carcinoma (EP-NEC); Gastroenteropancreatic NEC (GEP NEC); Neuroendocrine Prostate Cancer (NEPC) Moonlight Bio, Inc 2026-06-23 PHASE1
NCT07366658 RECRUITING SCLC, Extensive Stage; Neuroendocrine Tumors Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2026-02-20 PHASE1
NCT03000257 COMPLETED Drug: Venetoclax|Drug: Rovalpituzumab Tesirine|Drug: ABBV-18 Advanced Solid Tumors AbbVie 2016-12-14 PHASE1
NCT03061812 COMPLETED Drug: Rovalpituzumab tesirine|Drug: Topotecan|Drug: Dexameth Small Cell Lung Cancer AbbVie 2017-04-11 PHASE3
NCT03543358 COMPLETED Drug: rovalpituzumab tesirine|Drug: rovalpituzumab tesirine Cancer AbbVie 2018-09-10 PHASE2
NCT03033511 TERMINATED Drug: Placebo for dexamethasone|Drug: Placebo for rovalpituz Small Cell Lung Cancer AbbVie 2017-02-07 PHASE3

(data from https://clinicaltrials.gov, updated on 2026-08-25)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.